A comparison of the ability of emodepside to inhibit pharyngeal pumping and locomotion in C. elegans expressing either slo-1 or kcnma1
Data are a summary of the effects of 100 nM and 10 μM emodepside from Figs. 5A and 6. The values are presented as percentage of control, where control is the average number of pumps (in the presence of 300 nM 5-HT) or body bends in worms on vehicle plates, assessed in parallel with the drug treatment group. Wild-type control are worms expressing the transformation marker myo-2::gfp.
| Percentage of Control | |||
|---|---|---|---|
| Pharyngeal Pumps 100 nM emo | Body Bends | ||
| 100 nM emo | 10 μM emo | ||
| % | |||
| Wild-type | 8 ± 2 (n = 4)* | 32 ± 4 (n = 10)* | 10 ± 2 (n = 10)* |
| slo-1(js379) | 99 ± 9 (n = 7) | 101 ± 8 (n = 10) | 96 ± 9 (n = 10) |
| js379;pslo-1:: slo-1 | 10 ± 6 (n = 8)* | 26 ± 5 (n = 10)* | 8 ± 2 (n = 10)* |
| js379;pslo-1:: kcnma1 | 117 ± 15 (n = 6) | 104 ± 6 (n = 10) | 68 ± 8 (n = 10)* |
emo, emodepside.
↵* Significantly different from control; one-way ANOVA with Bonferroni post hoc test.